Top

Published in:

01-04-2014 | Research Article

Association of the vascular endothelial growth factor (VEGF) gene single-nucleotide polymorphisms with osteosarcoma susceptibility in a Chinese population

Authors: Zhen Wang, Peng Wen, Xiaojun Luo, Xiaomin Fang, Qingfeng Wang, Feng Ma, Jinhan Lv

Published in: Tumor Biology | Issue 4/2014

Abstract

Osteosarcoma (OS) is the most common bone malignancy worldwide. The vascular endothelial growth factor (VEGF) gene plays an important role in the pathogenesis of OS. The objective of this study aimed to detect the potential association between VEGF genetic polymorphisms and OS susceptibility in Chinese Han population. We recruited 330 OS patients and 342 cancer-free controls in this case–control study. Three single-nucleotide polymorphisms (SNPs) (−634 G > C, +936 C > T, and +1612 G > A) of the VEGF gene were investigated by using polymerase chain reaction–restriction fragment length polymorphism (PCR–RFLP) method and confirmed by direct DNA sequencing. Among these SNPs, we found that the genotypes/alleles of +936 C > T were statistically associated with the increased risk of OS (TT versus (vs.) CC: OR = 2.70, 95 % CI 1.34–5.45, χ² = 8.2271, p = 0.0041; T vs. C: OR = 1.31, 95 % CI 1.02–1.68, χ² = 4.3861, p = 0.0362). The T allele and TT genotype of +936 C > T could be factors that increase the risk for susceptibility to OS. The results from this study suggest that VEGF genetic variants are potentially related to OS susceptibility in Chinese Han population and might be used as molecular markers for assessing OS susceptibility.

Mirabello L, Troisi RJ, Savage SA. Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer. 2009;115(7):1531–43. doi:10.1002/cncr.24121.PubMedCentralPubMedCrossRef

Hameed M, Dorfman H. Primary malignant bone tumors—recent developments. Semin Diagn Pathol. 2011;28(1):86–101.PubMedCrossRef

Zhu L, McManus MM, Hughes DP. Understanding the biology of bone sarcoma from early initiating events through late events in metastasis and disease progression. Frontiers Oncology. 2013;3:230. doi:10.3389/fonc.2013.00230.CrossRef

Patio-Garcia A, Sotillo-Pieiro E, Modesto C, Sierrases-Maga L. Analysis of the human tumour necrosis factor-alpha (TNFalpha) gene promoter polymorphisms in children with bone cancer. J Med Genet. 2000;37(10):789–92.PubMedCrossRef

Savage SA, Burdett L, Troisi R, Douglass C, Hoover RN, Chanock SJ. Germ-line genetic variation of TP53 in osteosarcoma. Pediatr Blood Cancer. 2007;49(1):28–33. doi:10.1002/pbc.21077.PubMedCrossRef

Savage SA, Woodson K, Walk E, Modi W, Liao J, Douglass C, et al. Analysis of genes critical for growth regulation identifies insulin-like growth factor 2 receptor variations with possible functional significance as risk factors for osteosarcoma. Cancer Epidemiol, Biomarkers Prev. 2007;16(8):1667–74. doi:10.1158/1055-9965.EPI-07-0214.CrossRef

Koshkina NV, Kleinerman ES, Li G, Zhao CC, Wei Q, Sturgis EM. Exploratory analysis of Fas gene polymorphisms in pediatric osteosarcoma patients. J Pediatr Hematol/Oncol. 2007;29(12):815–21. doi:10.1097/MPH.0b013e3181581506.CrossRef

Toffoli G, Biason P, Russo A, De Mattia E, Cecchin E, Hattinger CM, et al. Effect of TP53 Arg72Pro and MDM2 SNP309 polymorphisms on the risk of high-grade osteosarcoma development and survival. Clin Cancer Res. 2009;15(10):3550–6. doi:10.1158/1078-0432.CCR-08-2249.PubMedCrossRef

Hu YS, Pan Y, Li WH, Zhang Y, Li J, Ma BA. Association between TGFBR1*6A and osteosarcoma: a Chinese case-control study. BMC Cancer. 2010;10:169. doi:10.1186/1471-2407-10-169.PubMedCentralPubMedCrossRef

10.

Mirabello L, Berndt SI, Seratti GF, Burdett L, Yeager M, Chowdhury S, et al. Genetic variation at chromosome 8q24 in osteosarcoma cases and controls. Carcinogenesis. 2010;31(8):1400–4. doi:10.1093/carcin/bgq117.PubMedCentralPubMedCrossRef

11.

Mirabello L, Yu K, Berndt SI, Burdett L, Wang Z, Chowdhury S, et al. A comprehensive candidate gene approach identifies genetic variation associated with osteosarcoma. BMC Cancer. 2011;11:209. doi:10.1186/1471-2407-11-209.PubMedCentralPubMedCrossRef

12.

He J, Wang J, Wang D, Dai S, Yv T, Chen P, et al. Association analysis between genetic variants of MDM2 gene and osteosarcoma susceptibility in Chinese. Endocrine Journal. 2013;60(11):1215–20.

13.

Savage SA, Mirabello L, Wang Z, Gastier-Foster JM, Gorlick R, Khanna C, et al. Genome-wide association study identifies two susceptibility loci for osteosarcoma. Nat Genet. 2013;45(7):799–803. doi:10.1038/ng.2645.PubMedCentralPubMedCrossRef

14.

Kushner EJ, Bautch VL. Building blood vessels in development and disease. Curr Opin Hematol. 2013;20(3):231–6. doi:10.1097/MOH.0b013e328360614b.PubMed

15.

Roy H, Bhardwaj S, Yla-Herttuala S. Biology of vascular endothelial growth factors. FEBS Lett. 2006;580(12):2879–87. doi:10.1016/j.febslet.2006.03.087.PubMedCrossRef

16.

Yang J, Yang D, Sun Y, Sun B, Wang G, Trent JC, et al. Genetic amplification of the vascular endothelial growth factor (VEGF) pathway genes, including VEGFA, in human osteosarcoma. Cancer. 2011;117(21):4925–38. doi:10.1002/cncr.26116.PubMedCentralPubMedCrossRef

17.

Kaya M, Wada T, Akatsuka T, Kawaguchi S, Nagoya S, Shindoh M, et al. Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis. Clin Cancer Res. 2000;6(2):572–7.PubMed

18.

DuBois S, Demetri G. Markers of angiogenesis and clinical features in patients with sarcoma. Cancer. 2007;109(5):813–9. doi:10.1002/cncr.22455.PubMedCrossRef

19.

Lammli J, Fan M, Rosenthal HG, Patni M, Rinehart E, Vergara G, et al. Expression of vascular endothelial growth factor correlates with the advance of clinical osteosarcoma. Int Orthop. 2012;36(11):2307–13. doi:10.1007/s00264-012-1629-z.PubMedCentralPubMedCrossRef

20.

Vincenti V, Cassano C, Rocchi M, Persico G. Assignment of the vascular endothelial growth factor gene to human chromosome 6p21.3. Circulation. 1996;93(8):1493–5.PubMedCrossRef

21.

Watson CJ, Webb NJ, Bottomley MJ, Brenchley PE. Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production. Cytokine+. 2000;12(8):1232–5. doi:10.1006/cyto.2000.0692.PubMed

22.

Renner W, Kotschan S, Hoffmann C, Obermayer-Pietsch B, Pilger E. A common 936 C/T mutation in the gene for vascular endothelial growth factor is associated with vascular endothelial growth factor plasma levels. J Vasc Res. 2000;37(6):443–8. doi:10.1159/000054076.PubMedCrossRef

23.

Lee SJ, Lee SY, Jeon HS, Park SH, Jang JS, Lee GY, et al. Vascular endothelial growth factor gene polymorphisms and risk of primary lung cancer. Cancer Epidemiol, Biomarkers Prev. 2005;14(3):571–5. doi:10.1158/1055-9965.EPI-04-0472.CrossRef

24.

Hofmann G, Langsenlehner U, Renner W, Langsenlehner T, Yazdani-Biuki B, Clar H, et al. Common single-nucleotide polymorphisms in the vascular endothelial growth factor gene and colorectal cancer risk. J Cancer Res Clin Oncol. 2008;134(5):591–5. doi:10.1007/s00432-007-0322-x.PubMedCrossRef

25.

Yapijakis C, Vairaktaris E, Vassiliou S, Vylliotis A, Nkenke E, Nixon AM, et al. The low VEGF production allele of the +936C/T polymorphism is strongly associated with increased risk for oral cancer. J Cancer Res Clin Oncol. 2007;133(10):787–91. doi:10.1007/s00432-007-0240-y.PubMedCrossRef

26.

Li YZ, Wang LJ, Li X, Li SL, Wang JL, Wu ZH, et al. Vascular endothelial growth factor gene polymorphisms contribute to the risk of endometriosis: an updated systematic review and meta-analysis of 14 case-control studies. Genet Mol Res. 2013;12(2):1035–44. doi:10.4238/2013.April.2.20.PubMedCrossRef

27.

Jiang Y, Tang JY, Wu Y, Zhao TF. Vascular endothelial growth factor gene polymorphisms and the risk of endometriosis: a systematic review. Zhonghua Fu Chan Ke Za Zhi. 2012;47(3):179–84.PubMed

28.

Zhou Y, Hu W, Zhuang W, Liu GJ, Wu TX, Yao X, et al. Vascular endothelial growth factor (VEGF) +936 C/T gene polymorphisms and gastric cancer risk: a meta-analysis involving 4,138 subjects. Int J Biol Markers. 2010;25(4):213–8.PubMed

29.

Jiang H, Lian M, Xie J, Li J, Wang M. Three single-nucleotide polymorphisms of the vascular endothelial growth factor (VEGF) gene and glioma risk in a Chinese population. The Journal of International Medical Research. 2013. doi:10.1177/0300060513498667.

30.

Jain L, Vargo CA, Danesi R, Sissung TM, Price DK, Venzon D, et al. The role of vascular endothelial growth factor SNPs as predictive and prognostic markers for major solid tumors. Mol Cancer Ther. 2009;8(9):2496–508. doi:10.1158/1535-7163.MCT-09-0302.PubMedCentralPubMedCrossRef

31.

Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer. 2002;2(10):795–803. doi:10.1038/nrc909.PubMedCrossRef

32.

Simonetti O, Lucarini G, Rubini C, Goteri G, Zizzi A, Staibano S, et al. Microvessel density and VEGF, HIF-1alpha expression in primary oral melanoma: correlation with prognosis. Oral Dis. 2013;19(6):620–7. doi:10.1111/odi.12048.PubMedCrossRef

33.

Bandoh N, Hayashi T, Takahara M, Kishibe K, Ogino T, Katayama A, et al. VEGF and bFGF expression and microvessel density of maxillary sinus squamous cell carcinoma in relation to p53 status, spontaneous apoptosis and prognosis. Cancer Lett. 2004;208(2):215–25. doi:10.1016/j.canlet.2003.11.031.PubMedCrossRef

34.

Iordache S, Saftoiu A, Georgescu CV, Ramboiu S, Gheonea DI, Filip M, et al. Vascular endothelial growth factor expression and microvessel density—two useful tools for the assessment of prognosis and survival in gastric cancer patients. J Gastrointest Liver Dis. 2010;19(2):135–9.

35.

Koukourakis MI, Papazoglou D, Giatromanolaki A, Bougioukas G, Maltezos E, Sivridis E. VEGF gene sequence variation defines VEGF gene expression status and angiogenic activity in non-small cell lung cancer. Lung Cancer. 2004;46(3):293–8. doi:10.1016/j.lungcan.2004.04.037.PubMedCrossRef

36.

Krippl P, Langsenlehner U, Renner W, Yazdani-Biuki B, Wolf G, Wascher TC, et al. A common 936 C/T gene polymorphism of vascular endothelial growth factor is associated with decreased breast cancer risk. Int J Cancer (Journal International du Cancer). 2003;106(4):468–71. doi:10.1002/ijc.11238.PubMedCrossRef

37.

Kataoka N, Cai Q, Wen W, Shu XO, Jin F, Gao YT, et al. Population-based case-control study of VEGF gene polymorphisms and breast cancer risk among Chinese women. Cancer Epidemiol, Biomark Prev. 2006;15(6):1148–52. doi:10.1158/1055-9965.EPI-05-0871.CrossRef

38.

Jakubowska A, Gronwald J, Menkiszak J, Gorski B, Huzarski T, Byrski T, et al. The VEGF_936_C > T 3'UTR polymorphism reduces BRCA1-associated breast cancer risk in Polish women. Cancer Lett. 2008;262(1):71–6. doi:10.1016/j.canlet.2007.11.029.PubMedCrossRef

39.

Bae SJ, Kim JW, Kang H, Hwang SG, Oh D, Kim NK. Gender-specific association between polymorphism of vascular endothelial growth factor (VEGF 936 C > T) gene and colon cancer in Korea. Anticancer Res. 2008;28(2B):1271–6.PubMed

40.

Bae SJ, Ahn DH, Hong SP, Kang H, Hwang SG, Oh D, et al. Gender-specific association between polymorphism of vascular endothelial growth factor (VEGF 936C > T) gene and patients with stomach cancer. Yonsei Med J. 2008;49(5):783–91. doi:10.3349/ymj.2008.49.5.783.PubMedCentralPubMedCrossRef

41.

Yu F, Miao J. Significant association between cytotoxic T lymphocyte antigen 4 +49G > A polymorphism and risk of malignant bone tumors. Tumour Biology. 2013. doi:10.1007/s13277-013-0908-7.

42.

Gu F, Pfeiffer RM, Bhattacharjee S, Han SS, Taylor PR, Berndt S, et al. Common genetic variants in the 9p21 region and their associations with multiple tumours. Br J Cancer. 2013;108(6):1378–86. doi:10.1038/bjc.2013.7.PubMedCentralPubMedCrossRef

43.

He M, Wang Z, Zhao J, Chen Y, Wu Y. COL1A1 polymorphism is associated with risks of osteosarcoma susceptibility and death. Tumour Biology. 2013. doi:10.1007/s13277-013-1172-6.

44.

Wang J, Nong L, Wei Y, Qin S, Zhou Y, Tang Y. Association of interleukin-12 polymorphisms and serum IL-12p40 levels with osteosarcoma risk. DNA Cell Biol. 2013;32(10):605–10. doi:10.1089/dna.2013.2098.PubMedCrossRef

Title: Association of the vascular endothelial growth factor (VEGF) gene single-nucleotide polymorphisms with osteosarcoma susceptibility in a Chinese population
Authors: Zhen Wang
Peng Wen
Xiaojun Luo
Xiaomin Fang
Qingfeng Wang
Feng Ma
Jinhan Lv
Publication date: 01-04-2014
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 4/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-013-1475-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2014

RETRACTED ARTICLE: Steroid receptor co-activator-3 promotes osteosarcoma progression through up-regulation of FoxM1

Overexpression of miR-145 increases the sensitivity of vemurafenib in drug-resistant colo205 cell line

Breast cancer sentinel lymph node mapping using near-infrared guided indocyanine green in comparison with blue dye

Decorin-mediated inhibition of cholangiocarcinoma cell growth and migration and promotion of apoptosis are associated with E-cadherin in vitro

Combining transarterial chemoembolization with radiofrequency ablation for hepatocellular carcinoma

Letter regarding Wang et al. entitled “Effects of murine double minute 2 polymorphisms on the risk and survival of osteosarcoma: a systemic review and meta-analysis”

Keynote webinar | Spotlight on antibody–drug conjugates in cancer